Regulatory context
Regulatory context; not efficacy evidence
No matched controlled clinical study of this exact preparation was verified in this source audit.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.
ARTEMIDA: 503 adults at least 60 years old with poststroke cognitive impairment.
Reported findings. Six-month ADAS-cog+ difference favored Actovegin by 2.3 points; clinical importance uncertain.
Nonresponse. NIHSS and dementia diagnoses showed no significant between-group difference.
Harms. Cerebrovascular events 14 versus 7, nonsignificant; adverse-event discontinuations 21/250 versus 12/253.
Limits. Spontaneous adverse-event reporting without prespecified safety endpoints. Commercial supplier describes a calf-blood hemoderivative; this does not verify composition or manufacturing equivalence. ActoGeniX company bacterial therapeutics are a different identity and are not joined to this catalog product.
Preparation: Medicinal Actovegin calf-blood hemoderivative; vendor Actogenix equivalence unverified. Route: Intravenous then oral alongside standard stroke care.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.